<DOC>
	<DOCNO>NCT02315235</DOCNO>
	<brief_summary>To investigate efficacy safety autologous peripheral blood stem cell base therapy patient diabetic painful neuropathy .</brief_summary>
	<brief_title>The Peripheral Mobilized Mononuclear Cell-based Therapy Patient With Diabetic Neuropathy</brief_title>
	<detailed_description>Diabetic painful neuropathy prevalent , disable disorder . Currently , effective treatment glucose control pain management . Diabetic neuropathy characterize reduction vascularity peripheral nerve deficiency neurotrophic angiogenic factor . Recent study show bone marrow ( BM ) -derived stem progenitor cell favorable effect repair cardiovascular disease . Since BM-derived stem progenitor cell contain various angiogenic neurotrophic factor , cell attempt treat experimental diabetic neuropathy , turn effective reversing various manifestation experimental diabetic neuropathy . However , stem-cell therapy proven human study . Therefore , investigate efficacy safety autologous peripheral blood stem cell injection diabetic neuropathy .</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>symptomatic diabetic neuropathy moderate pain 3 month Michigan Neuropathy Screening Instrument ( MNSI ) &gt; 3 3/day mean pain scale &gt; NRS 4 Body weight &gt; 50 kg systolic blood pressure : 90150 mmHg , Diastolic blood pressure &lt; 100 mmHg , Body temperature &lt; 37.5â„ƒ , Pulse rate : 50100/min cause neuropathy symptomatic peripheral vessel disease skin lesion arthritis central neuronal disease drug addiction abuse Aspartate aminotransferase Alanine aminotransferase &gt; 1.5 time upper normal limit range Creatinine clearance rate &lt; 60ml/min dialysis Myocardial infarction , unstable angina heart failure diagnose 3 month psychologic disorder pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>